Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies

  title={Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies},
  author={Ali Razaghi and Kirsten Heimann and Patrick M. Schaeffer and Spencer B Gibson},
Cancer is a primary cause of human fatality and conventional cancer therapies, e.g., chemotherapy, are often associated with adverse side-effects, tumor drug-resistance, and recurrence. Molecularly targeted therapy, composed of small-molecule inhibitors and immunotherapy (e.g., monoclonal antibody and cancer vaccines), is a less harmful alternative being more effective against cancer cells whilst preserving healthy tissues. Drug-resistance, however, caused by negative regulation of cell death… 
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
An overview of the molecular mechanisms initiated by conventional therapies and the impact of treatment-induced TCD on the TME is sought and some perspectives on how to circumvent tolerogenic effects by adequate treatment selection and manipulation of key signaling cascades are provided.
Curcumin effect on cancer cells' multidrug resistance: An update
Curcumin is suggested as a potent chemosensitizer in cancers because it has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels.
Therapeutic Drugs and Natural Products: The Effect of Suppressing Heat Shock Proteins (Hsp) in Brain Tumors
This chapter puts emphasis on application of HSP in the treatment of brain tumors and the potential of therapeutic drugs and/or natural products in these tumors.
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
The current findings of ferroptosis regulation are reviewed and especially focus on the function of ncRNAs in mediating the process of cell ferroPTotic death and on how ferroaptosis was in relation to other regulated cell deaths.
SPIB promotes anoikis resistance via elevated autolysosomal process in lung cancer cells
It is identified that upon matrix deprivation, the lymphocyte lineage‐specific Ets transcription factor SPIB was activated and directly enhanced SNAP47 transcription in certain lung cancer cells and delineate an important role of SPIB in autophagy‐mediated anoikis resistance in Lung cancer cells.
Cell death rocks
In a large cohort of early stage invasive breast cancer patients it was found that caspase-3 expression was associated to adverse cancer-specific survival, and the impact of these observations underline that it is of extreme importance to understand the mechanisms of cell death, in order to understand e.g. the mechanism of disease.
Programmed cell death, redox imbalance, and cancer therapeutics.
FrontCold atmospheric plasma is brought affront cold atmospheric plasma as an emerging redox controller with translational potential in clinics by addressing differences and similarities among programmed cell death events regarding their associations with redox imbalance.
Gold nanoparticles induce apoptosis in HCT-116 colon cancer cell line.
It is shown that AuNPs cause apoptosis at the half-maximal inhibitory concentration in the HCT-116 tumor cells during 48 h of incubation.
Synergistic effects of CP-25 and 5-fluorouracil on the hepatocellular carcinoma in vivo and in vitro through regulating activating mitochondrial pathway
This research provides a novel and effective combination strategy for the therapy of HCC but also provides an experimental basis for the development of CP-25 and 5-Fu compound preparation.


The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
The current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis are summarized.
Targeting cell death signalling in cancer: minimising ‘Collateral damage'
The importance of an in-depth mechanistic understanding of both apoptotic and non-apoptotic functions of those proteins under investigation as anti-cancer drug targets are highlighted and some novel approaches to sensitise cancer cells to apoptosis are outlined, thereby improving the efficacy of existing therapies when used in combination with novel targeted agents.
Biomarkers for Immunotherapy: Current Developments and Challenges.
The status of current biomarker candidates is explored and both tumor-infiltrating lymphocytes and PD-L1 expression within the tumor microenvironment have been recognized as having both prognostic and predictive value for patients treated with immunotherapy.
Current and Emerging Biomarkers of Cell Death in Human Disease
Recent knowledge about cell death is summarized, current and emerging biomarkers of cell death are surveyed, and the relationship with human diseases is discussed.
Resistance to Cell Death and Its Modulation in Cancer Stem Cells.
  • A. Safa
  • Biology
    Critical reviews in oncogenesis
  • 2016
A review article expands on the CSC hypothesis and paradigm with respect to major signaling pathways and effectors that regulate CSC apoptosis resistance and their therapeutic potential for making tumors more responsive to therapy.
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
The pipeline of Akt inhibitors and their preclinical and clinical examination status are explored, presenting the potential clinical application of these agents as a monotherapy or in combination with ionizing radiation, other targeted therapies, or chemotherapy.
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
The role of NF-κB in cancer and in the development of resistance, particularly cisplatin is described and the potential benefits and disadvantages of targeting NF-kkB signaling by pharmacological intervention will be addressed.
Relevance of necroptosis in cancer
A better knowledge of the cascade of events regulating necroptosis is expected to assess the feasibility of its therapeutic exploitation for cancer therapy, as accumulating evidence has shown that ne croptosis promotes anticancer immune response.
Drug Resistance in Cancer: An Overview
The current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance are outlined.
EGFR Family Members’ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer
The current understanding of EGFR family member regulation of autophagy in cancer cells and how new therapeutic strategies could be developed to overcome drug resistance are summarized.